Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Clarksterh who wrote (1289)	11/1/2004 11:53:50 PM
From: marin	Read Replies (1) of 1386

"Marin - There is no further subdivision between GCS 4-6 and 7-8. Clark - I assume that they mean only that before unblinding that they do not know the breakdown? Not that the Statistical Analysis Plan will only group them that coarsely." The way I wrote that statement was out of context. At one time, there was a thought among investors that there would be a division between 4-6 and 7-8. What exactly that division would mean for the trial results I was never quite clear on, but Management never gave us that information as far as I know. But, anyway, that notion developed a life of its own and was refuted today by management. The trial outcome is GOSE at 6 months. It would have been interesting today, if management had given us the final MGCS average. It's funny, they didn't mind publicizing the average at around the 500 and 700 patient mark, but the trial is finished so they don't feel comfortable. Sigh... jonmarin

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next